Page 270 - Vitamin D and Cancer

11 Vitamin D and Hematologic Malignancies 257

Reference [53] [134] [156] [44] [157] [45]

Occasional minor response Markedly decreased progression to AML 10/14 (71%) responded d Occasional minor response No therapeutic effect No therapeutic effect

Efficiency

No. of Patients a 18 15 14 12 26 15

Treatment duration (months) 3 17 c 9–27 £ 9 5 c 3
Trials of vitamin D compounds in myelodysplastic syndrome (MDS)

Dose/day (mg) 2 4–6 0.25 – 0.75 8 – 56 50 – 100 12.5

Hyper-calcemia + (50%) b + (13%) b – – – –

Another name Calcitriol Alfacalcidol Calcitriol Paricalcitol e Cholecalciferol Doxercalciferol f a Only trials with ³12 patients are listed b Percentage individuals who developed hypercalcemia while on trial d Criteria for response was not stringent e Abbott Laboratories code name is Paricalcitol f Bon

Table 11.1 Compound 1,25(OH) 2 D 3 1(OH)D 3 1,25(OH) 2 D 3 19-nor-1,25(OH) 2 D 2 Vitamin D 3 1(OH)D 2 c Median